Article Sidebar
Views PDF: 1
EFFICACY OF CEFTAZIDIME/AVIBACTAM IN THE TREATMENT OF SUPERINFECTION IN COVID-19 PATIENTS AT HOSPITAL FOR TROPICAL DISEASES
Main Article Content
Abstract
Introduction: Carbapenem resistant Gram-negative bacteria (CRGNB) are a pressing infectious disease challenge, especially in the COVID-19 pandemic. According to IDSA, ceftazidime/avibactam (CZA) is one of the preferred options for CRGNB. This study aimed to investigate the effectiveness of CZA in the treatment of in COVID-19 patients.
Materials and methods: A cross-sectional descriptive study was conducted in 118 COVID-19 patients with who indicated CZA treatment from 6/2021 to 6/2022.
Results: The median age of patients in the study population was 58. Most patients were diagnosed with pneumoniae (77.12%). K. pneumoniae was the most common bacteria in the specimen (75.21%). Carbapenemase genes were detected in 60 specimens, of which the majority was OXA-48 (96.67%). Most patients received CZA as combination (94.92%) and the median duration of treatment with CZA was 10 days. Age ≥ 60, unconsciousness, shock, and OXA-48 were associated factors with mortality after 7 days of treatment with CZA. Using CZA in patients with positive PCR OXA-48 may increase survival at 7 days. Elderly patients, unconsciousness, shock, and urinary tract infection (UTI) were associated with mortality outcome.
Conclusions: CZA is one of the antibiotics considered for treatment CRGNB, especially in CRE producing OXA-48 carbapenemase.
Article Details
Keywords
Ceftazidime/avibactam, infection, COVID-19
References
2. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025.
3. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficultto-Treat Resistance (DTR-P. . Clin Infect Dis. 2022;75(2):187-212. doi:10.1093/cid/ciac268.
4. Soriano A, Montravers P, Bassetti M, et al. The Use and Effectiveness of Ceftazidime-Avibactam in Real-World Clinical Practice: EZTEAM Study. Infect Dis Ther. 2023;12(3):891-917. doi:10.1007/
s40121-023-00762-9.
5. Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2019;69(Suppl 7):S565-S575. doi:10.1093/cid/ciz830.
6. Stewart A, Harris P, Henderson A, Paterson D. Treatment of Infections by OXA-48-Producing
Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(11). doi:10.1128/AAC.01195-18.
7. De la Calle C, Rodríguez O, Morata L, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agents. 2019;53(4):520-524. doi:https://doi.org/10.1016/j.ijantimicag.2018.11.015.
8. Alraddadi BM, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis. 2019;19(1):772. doi:10.1186/s12879-019-4409-1.
9. Goncalves Mendes Neto A, Lo KB, Wattoo A, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med Virol. 2021;93(3):1489-1495. doi:10.1002/jmv.26441.